Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 32.50% | 26.56% | 8.85% | -5.22% | -10.50% |
| Total Depreciation and Amortization | 20.31% | 12.89% | 38.55% | 73.90% | 70.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 191.99% | 92.19% | 63.65% | -9.18% | -42.93% |
| Change in Net Operating Assets | -419.47% | -326.10% | -237.50% | -153.71% | 295.87% |
| Cash from Operations | 12.71% | 29.86% | -4.77% | -22.51% | -8.11% |
| Capital Expenditure | -18.11% | 36.04% | 95.36% | 26.36% | -16.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | 100.00% | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 140.03% | 35.45% | -34.68% | -134.43% | -2,097.39% |
| Cash from Investing | 132.50% | 38.24% | 125.65% | -172.69% | -15,901.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 177.79% | -76.26% | 11,500.68% | -23.77% | -99.40% |
| Repurchase of Common Stock | -373.12% | -1,556.20% | -232.23% | -143.70% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 140.02% | -79.31% | 14,809.76% | -25.02% | -99.50% |
| Foreign Exchange rate Adjustments | -138.99% | 162.87% | 96.68% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.27% | -271.22% | 137.28% | -113.06% | -234.81% |